Golidocitinib Combined With GemOx in RR PTCL
NCT07279584 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31
Last updated 2025-12-12
Summary
The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL
Conditions
- Peripheral T-cell Lymphomas (PTCL)
Interventions
- DRUG
-
golidocitinib
150mg qd po
- DRUG
-
GEMOX
Gemcitabine: 1000mg/m2, d1; Oxaliplatin:100mg/m2, d1
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-20
- Primary Completion
- 2026-12-31
- Completion
- 2027-12-31
More Related Trials
-
A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
NCT06963632 ·Status: NOT_YET_RECRUITING
-
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
NCT02267915 ·Status: UNKNOWN ·Phase: PHASE2
-
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
NCT05186558 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
NCT06739265 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192 ·Status: UNKNOWN ·Phase: NA
-
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
NCT06086197 ·Status: RECRUITING ·Phase: PHASE2
-
A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00301301 ·Status: COMPLETED
-
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07122609 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
NCT05833763 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
NCT00169195 ·Status: COMPLETED ·Phase: PHASE2
-
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT07231250 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255 ·Status: RECRUITING ·Phase: PHASE3
-
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
NCT01321541 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
NCT05381506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
NCT07326371 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
Gemcitabine for Marginal Zone Lymphoma
NCT00337259 ·Status: TERMINATED ·Phase: PHASE2
-
Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
NCT00954005 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
NCT06929624 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162 ·Status: RECRUITING ·Phase: PHASE3
-
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
NCT06712173 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
NCT07209163 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2